Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7336752 | 0.83 | SHMT2 (0.51) | HDAC1PRSS1TPSAB1CACNA1HNPC1 | |
| SCHEMBL27215273 | 0.81 | NPC1 (0.51) | HDAC1LMNAHTTNPSR1NPC1 | |
| SCHEMBL3715020 | 0.81 | CA1 (0.39) | LMNAHTTNPC1 | |
| SCHEMBL29302722 | 0.75 | PRSS1 (0.41) | HDAC1PRSS1TPSAB1CACNA1HLMNA | |
| SCHEMBL29940493 | 0.75 | PRSS1 (0.41) | HDAC1PRSS1TPSAB1CACNA1HLMNA | |
| SCHEMBL30689233 | 0.73 | PRSS1 (0.45) | HDAC1PRSS1TPSAB1CACNA1HNPC1 | |
| SCHEMBL30819391 | 0.72 | PRSS1 (0.49) | HDAC1PRSS1TPSAB1CACNA1HNPC1 | |
| SCHEMBL8426730 | 0.72 | PRSS1 (0.56) | PRSS1TPSAB1CACNA1HNPC1 | |
| SCHEMBL5733475 | 0.72 | NPC1 (0.41) | HDAC1HTTNPC1 | |
| SCHEMBL13191113 | 0.71 | MEN1 (0.44) | HDAC1LMNAHTTNPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8648066-B2 | Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture | EXELIXIS, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2640366-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012068096-A2 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | HDAC1 293/4885PRSS1 782/4885TPSAB1 598/4885 |
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | HDAC1 247/4885PRSS1 699/4885TPSAB1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.